Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MeiraGTx Holdings PLC (MGTX : NSDQ)
 
 • Company Description   
MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York.

Number of Employees: 296

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.48 Daily Weekly Monthly
20 Day Moving Average: 125,145 shares
Shares Outstanding: 44.71 (millions)
Market Capitalization: $379.15 (millions)
Beta: 1.83
52 Week High: $24.33
52 Week Low: $8.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -32.38% -25.90%
12 Week -39.73% -34.60%
Year To Date -64.28% -57.52%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
450 East 29th Street 14th Floor
-
NEW YORK,NY 10016
USA
ph: 646-860-7985
fax: -
investors@meiragtx.com http://www.meiragtx.com
 
 • General Corporate Information   
Officers
Alexandria Forbes - Chief Executive Officer;President and Director
Keith R. Harris - Chairman of the Board and Director
Richard Giroux - Chief Financial Officer
Martin Indyk - Director
Ellen Hukkelhoven - Director

Peer Information
MeiraGTx Holdings PLC (CORR.)
MeiraGTx Holdings PLC (RSPI)
MeiraGTx Holdings PLC (CGXP)
MeiraGTx Holdings PLC (BGEN)
MeiraGTx Holdings PLC (GTBP)
MeiraGTx Holdings PLC (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G59665102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 44.71
Most Recent Split Date: (:1)
Beta: 1.83
Market Capitalization: $379.15 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.58 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.12 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.35
Price/Cash Flow: -
Price / Sales: 9.79
EPS Growth
vs. Year Ago Period: -29.63%
vs. Previous Quarter: -218.18%
Sales Growth
vs. Year Ago Period: 22.59%
vs. Previous Quarter: -73.23%
ROE
03/31/22 - -47.01
12/31/21 - -39.79
09/30/21 - -37.57
ROA
03/31/22 - -28.11
12/31/21 - -24.67
09/30/21 - -24.03
Current Ratio
03/31/22 - 2.18
12/31/21 - 2.69
09/30/21 - 2.97
Quick Ratio
03/31/22 - 2.18
12/31/21 - 2.69
09/30/21 - 2.97
Operating Margin
03/31/22 - -224.55
12/31/21 - -211.03
09/30/21 - -391.81
Net Margin
03/31/22 - -224.55
12/31/21 - -211.03
09/30/21 - -391.81
Pre-Tax Margin
03/31/22 - -224.55
12/31/21 - -211.03
09/30/21 - -391.81
Book Value
03/31/22 - 3.61
12/31/21 - 4.17
09/30/21 - 4.24
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.13
12/31/21 - 0.11
09/30/21 - 0.11
Debt-to-Capital
03/31/22 - 11.41
12/31/21 - 9.89
09/30/21 - 10.17
 

Powered by Zacks Investment Research ©